DBV Technologies S.A. (NASDAQ:DBVT) hit a new 52-week high on Friday after Citigroup raised their price target on the stock from $43.00 to $57.00. Citigroup currently has a buy rating on the stock. DBV Technologies traded as high as $47.37 and last traded at $47.41, with a volume of 168,689 shares traded. The stock had previously closed at $46.17.

Other research analysts also recently issued reports about the company. Deutsche Bank AG initiated coverage on DBV Technologies in a report on Friday, June 23rd. They set a “buy” rating and a $46.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of DBV Technologies in a report on Thursday, July 6th. BidaskClub raised DBV Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research raised DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 target price on the stock in a report on Tuesday, August 29th. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $54.86.

Large investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of DBV Technologies in the 2nd quarter valued at about $222,000. Victory Capital Management Inc. acquired a new position in shares of DBV Technologies in the 1st quarter valued at about $303,000. Airain ltd acquired a new position in shares of DBV Technologies in the 2nd quarter valued at about $333,000. Sit Investment Associates Inc. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at about $698,000. Finally, Jane Street Group LLC acquired a new position in shares of DBV Technologies in the 1st quarter valued at about $853,000. 45.52% of the stock is currently owned by institutional investors.

The stock’s 50-day moving average price is $43.87 and its 200 day moving average price is $38.53. The firm’s market cap is $2.20 billion.

COPYRIGHT VIOLATION NOTICE: “DBV Technologies S.A. (DBVT) Sets New 12-Month High on Analyst Upgrade” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/dbv-technologies-s-a-dbvt-sets-new-12-month-high-on-analyst-upgrade/1616388.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.